TABLE 2.
In vivo probe recovery of metronidazole and pharmacokinetic parameters determined at steady state by noncompartmental analysis in critical care patients receiving 30-min intravenous infusions of 500 mg of metronidazole every 8 h
| Patienta | Metronidazole pharmacokinetic parameterb |
|||||
|---|---|---|---|---|---|---|
| Vss,u (liters) | CLss,u (liters h−1) | t1/2 plasma (h) | t1/2 brain (h) | Brain ECF/unbound plasma AUC ratio | Mean % in vivo recovery ± SD (n = 3) | |
| Individual patients | ||||||
| P1 | 66.7 | 4.0 | 6.7 | 4.2 | 0.87 | 82.9 ± 0.5 |
| P2 | 56.4 | 3.4 | 9.2 | 4.5 | 0.83 | 79.5 ± 3.4 |
| P3 | 53.6 | 3.2 | 4.9 | 4.8 | 1.24 | 79.1 ± 1.4 |
| P4 | 65.6 | 3.9 | 4.3 | 4.4 | 1.16 | 73.9 ± 4.2 |
| Mean data | ||||||
| Mean | 60.6 | 7.9 | 6.3 | 4.5 | 1.02 | |
| SD | 6.6 | 2.8 | 2.2 | 0.2 | 0.19 | |
a
Both individual and mean patient data are presented.
b
The values for t1/2 plasma and t1/2 brain were not significantly different.